Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

10 treatments under study, led by Placebo

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
P 1 (3)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06161220Phase 1CompletedPrimary

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

NCT02820311Phase 1CompletedPrimary

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

NCT03709927Phase 1CompletedPrimary

4-way Crossover QT Evaluation in Healthy Subjects

Showing all 3 trials

Research Network

Common Treatments

  • Placebo1
  • Placebo Iv1
  • Moxifloxacin 400 Mg1
  • Carbidopa Capsule1
  • Td4208 175 Mcg1

Active Sponsors

  • Impax Laboratories Llc1
  • Nabriva Therapeutics Ag1
  • Mylan Inc1
  • Theravance Biopharma1

Activity Timeline